Related pages Drug Information Summaries Approval Process for New Cancer Treatments Access to Investigational Drugs: Q & A

This page contains brief information about gemtuzumab ozogamicin and a collection of links to more information from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA).

US Brand Name(s):		Mylotarg
FDA Approved:		Yes

Gemtuzumab ozogamicin is approved by the Food and Drug Administration (FDA) to treat acute myeloid leukemia in patients 60 years or older whose cancer has relapsed or who are not able to receive other chemotherapy.

Gemtuzumab ozogamicin is also being studied in the treatment of other types of cancer.

FDA Consumer Information Sheet on Gemtuzumab Ozogamicin - A lay language summary of important information about this drug that may include the following:

• FDA warnings or alerts about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This FDA consumer information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials for Gemtuzumab Ozogamicin - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.

Back to Top